A Multicenter, Randomized, Double-Blind, Placebo-Controlled and Open-Label Extension Phase III Study to Evaluate the Efficacy and Safety of ZM-H1505R (Canocapavir) in Combination With Nucleos(t)Ide Analog(NAs) Compared With NAs Monotherapy in Patients With Chronic Hepatitis B Who Have Received NAs Monotherapy for at Least 12 Months
Latest Information Update: 10 Aug 2025
At a glance
- Drugs Canocapavir (Primary) ; Entecavir; Tenofovir; Tenofovir alafenamide
- Indications Hepatitis B
- Focus Registrational; Therapeutic Use
- Sponsors Zhimeng Biopharma
Most Recent Events
- 10 Aug 2025 New trial record